Pharmacokinetics, Safety, and Pharmacodynamics of ATX-304 Na Salt in Obesity with Prediabetes or Type 2 Diabetes Mellitus: A Phase 1B Study

The primary objective of this study is to evaluate the **pharmacokinetics**, safety, and **pharmacodynamics** of treatment with ATX-304 Na Salt Tablets in individuals with **obesity** and either **prediabetes** or **type 2 diabetes mellitus**. Understanding the pharmacokinetics and pharmacodynamics is crucial for determining the appropriate dosing regimen and predicting the therapeutic effects and potential side effects of the treatment. This is particularly important in the context of obesity and related metabolic disorders, where effective management can significantly impact patient outcomes.

The clinical trial involves participants diagnosed with **obesity** accompanied by prediabetes or type 2 diabetes mellitus. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants are generally in a stable health condition, excluding those considered part of a vulnerable population. The selection process for the trial population is not specified by the sponsor, and the total number of participants has not been disclosed. Lifestyle considerations such as diet, physical activity, and habits are not detailed in the available data. The sponsor has not provided specific information regarding key inclusion or exclusion criteria for this study.

The clinical trial is a **Phase 3** study designed to evaluate the pharmacokinetics, safety, and pharmacodynamics of treatment with ATX-304 Na Salt Tablets in individuals diagnosed with **obesity with prediabetes or type 2 diabetes mellitus**. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The estimated duration of the trial spans from the recruitment start date on September 11, 2023, to the anticipated end date on June 30, 2025.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to confirm the diagnosis and ensure the absence of exclusion criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess the treatment's efficacy, and record any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the study is approximately 21 months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the study duration.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. Furthermore, the documentation lacks details on drug administration, dosing schedules, and participant compliance monitoring. As such, no further description of the treatments used in this clinical trial can be provided based on the available data.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on September 11, 2023, with an estimated completion date of June 30, 2025. The efficacy assessment will be conducted in accordance with the trial's protocol, which is structured to ensure rigorous evaluation of the treatment's impact. Although specific endpoints and methods for measuring efficacy are not detailed, the trial will adhere to standard practices for Phase 3 studies, which typically involve comprehensive data collection and analysis to determine the treatment's effectiveness. The trial's design will likely include periodic assessments at predetermined intervals to monitor progress and gather data on the treatment's efficacy. The results will be analyzed to provide insights into the treatment's potential benefits and inform future clinical decisions.